CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model

Neoplasia

Volumn 7, Issue 1, 2005, Pages 85-90

  Bar Yehuda, Sara ^a   Madi, Lea ^a   Silberman, Daniel ^a   Gery, Slosman ^a   Shkapenuk, Maya ^a   Fishman, Pnina ^a,b  

^a Can Fite BioPharma Ltd   (Israel)

^b Can File Biopharma Ltd   (Israel)

Author keywords

5 FU; A3 adenosine receptor agonist; Colon carcinoma; NF B; PKB Akt

Indexed keywords

1 DEOXY 1 [6 [[(IODOPHENYL)METHYL]AMINO] 9H PURIN 9 YL] N METHYL DEXTRO RIBOFURANURONAMIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR AGONIST; BROMINE DERIVATIVE; CASPASE 3; CYCLIN D1; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ADENOSINE; ADENOSINE A3 RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER INHIBITION; COLON CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; CLONOGENIC ASSAY; COLON TUMOR; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; PATHOLOGY; XENOGRAFT;

ADENOSINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL PROLIFERATION; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; RECEPTOR, ADENOSINE A3; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 13444255917     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04364     Document Type: Article

References (34)

1. Declan Fleming RY (1998). Colorectal cancer screening and follow-up. Surg Oncol 7, 125-537.
2. Van Triest B and Peters GJ (1999). Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 57, 179-194.
3. Kim R, Yamaguchi Y, and Toge T (2002). Adjuvant therapy for colorectal carcinoma. Anticancer Res 22, 2413-2418.
4. Becker K, Erckenbrecht JF, Haussinger D, and Frieling T (1999). Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 57, 475-484.
5. Bygrave HA, Geh JI, Jani Y, and Glynne-Jones (1998). Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature. Clin Oncol (R Coll Radiol) 10, 334-336.
6. Chau I and Chan SC (2003). Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin Colorectal Cancer 3, 19-33.
7. Constantinou M, Tsai JY, and Safran H (2003). Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Invest 21, 887-896.
8. Mitchell MS (2003). Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 52, 686-692.
9. Falcone A, Pfanner E, Brunetti I, Allegrini G, Lencioni M, Galli C, Masi G, Danesi R, Antonuzzo A, Del Tacca M, et al. (1998). Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU + LV-based chemotherapy. Tumori 84, 666-668.
10. Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, and Borea PA (2001). Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134, 1215-1226.
11. Suh BC, Kim TD, Lee JU, Seong JK, and Kim KT (2001). Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Br J Pharmacol 134, 132-142.
12. 3 adenosine receptor is highly expressed in tumor vs normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10, 4472-4479.
13. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269, 230-236.
14. 3AR agonist. Anticancer 23, 2077-2083.
15. 3 adenosine receptor agonist CF101. Br J Cancer 89, 1552-1558.
16. 3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB. Oncogene 23, 2465-2471.
17. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, and Khalili K (2002). Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21, 4060-4064.
18. 3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 278, 42121-42130.
19. Wang W and Cassidy J (2003). Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer 88, 624-629.
20. Fahy BN, Schlieman MG, Virudachalam S, and Bold RJ (2004). Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198, 591-599.
21. 3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 30, 1390-1398.
22. 3 receptor subtype. Curr Top Med Chem 3, 463-469.
23. Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
24. Madrid LV, Mayo MW, Reuther JY, and Baldwin AS Jr (2001). Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276, 18934-18940.
25. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, and Pestell RG (2001). NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12, 73-90.
26. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, and Heber D (2003). Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 22, 663-670.
27. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, and Korc M (1999). Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59, 3505-3511.
28. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Yamatsuji T, et al. (2003). Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 289, 27-35.
29. Krasilnikov MA (2000). Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry 65, 59-67.
30. Nakashio A, Fujita N, Rokudai S, Sato S, and Tsuruo T (2000). Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60, 5303-5309.
31. Saga Y, Mizukami H, Suzuki M, Kohno T, Urabe M, Ozawa K, and Sato I (2002). Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells. Clin Cancer Res 8, 1248-1252.
32. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, and Tindall DJ (2001). PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276, 38830-38836.
33. Yuan XJ and Whang YE (2002). PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21, 319-327.
34. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, and Chen KY (1995). Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 76, 2186-2192.